Mitochon Pharmaceuticals » Logo

Our Mission

Our mission is to bring forward meaningful drugs that work at the root of insidious diseases by direct modulation of the mitochondria’s physiology to attenuate disease progression.

A key thesis to our approach lies in the fact that modulating this entire organelle’s physiology by small increases in energy expenditure, there is pleiotropic cascade effect resulting in lowering damage by improved mitochondrial calcium (Ca2+) handling, shift in the mitochondrial population (mitophagy) towards improved function, lowering of ROS production (isoprostanes) for neuroprotection and increasing repair with induction of cAMP, CREB, and BDNF. Combined these effects have been shown to improve learning, cognition, and motor skills (Liu, D. 2015, Kandel, E.R. 2001). This has been shown repeatedly in models of energy expenditure (Geisler, J.G. 2019). With small increases in energy expenditure, pre-clinical data now exists to show that our two compounds MP-101 and MP-201:

Block demyelination and paralysis in Multiple Sclerosis (Bando, Y. 2019).
Protect of dopaminergic neurons in Parkinson’s Disease (Kishimoto, Y. 2020).
Preserve brain volume, motor skills and a reduction in ROSs with Huntington’s Disease (Duan, W. 2003 & Wu, B. 2017).
Improve motor skills and protection of neuromuscular junction (NMJ) associated with amyotrophic lateral sclerosis (ALS)—unpublished.
Accellerated learning and preservation of short-term memory in Alzheimer’s Disease (Geisler, J.G. 2017).
Neuroprotect in traumatic brain injury (TBI), sparing both tissue and improving cognition (Hubbard, W.B. 2018).
Our Mission » Mitochon PharmaceuticalsOur Mission » Mitochon Pharmaceuticals